ZWS Stock Analysis: Zurn Elkay Water Solutions | NYSE
Pollution & Treatment Controls | NYSE, USA | Market Cap: 7.827m USD | 12M Return: 3.8% | US98983L1089 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.6M
EPS Trend: 98.5%
Qual. Beats: 11
Rev. Trend: 96.2%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Zurn Elkay Water Solutions Corporation (NYSE: ZWS) is a U.S.-headquartered manufacturer of water management solutions, operating across the United States, Canada, and select international markets. Founded in 1900 and based in Milwaukee, Wisconsin, the company produces a broad portfolio of water dispensing and filtration products, water safety and control devices (such as backflow preventers and pressure reducing valves), drainage and flow systems, flush valves, faucets, sinks, restroom partitions, and hand dryers. Its products are sold under numerous brands, including Elkay, Halsey Taylor, Zurn, Wilkins, Hadrian, and Just, among others. The company markets to institutional, commercial, waterworks, and residential end users through independent sales representatives, plumbing wholesalers, and industry-specific distributors serving the waterworks, foodservice, industrial, janitorial, sanitation, and sitework industries.
Operating within the GICS Industrials sector and the Building Products sub-industry, Zurn Elkay employs a multi-brand strategy that allows it to target distinct niches within the broader plumbing and water infrastructure market. Its business model is predominantly B2B, relying on wholesale and distribution channels rather than direct-to-consumer sales, which is typical for commercial-grade plumbing and water management suppliers.
- Non-residential construction backlog drives drainage and water safety demand
- Lead-free plumbing regulations boost product replacement cycle
- Pure-play water focus supports margin expansion over multi-line peers
| Net Income: 276.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 2.88 > 1.0 |
| NWC/Revenue: 36.88% < 20% (prev 29.47%; Δ 7.41% < -1%) |
| CFO/TA 0.14 > 3% & CFO 401.4m > Net Income 276.1m |
| Net Debt (236.9m) to EBITDA (396.2m): 0.60 < 3 |
| Current Ratio: 3.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (169.2m) vs 12m ago -0.50% < -2% |
| Gross Margin: 44.77% > 18% (prev 44.55%; Δ 0.22% > 0.5%) |
| Asset Turnover: 63.94% > 50% (prev 60.81%; Δ 3.14% > 0%) |
| Interest Coverage Ratio: 11.97 > 6 (EBIT TTM 310.0m / Interest Expense TTM 25.9m) |
| A: 0.23 (Total Current Assets 953.1m - Total Current Liabilities 312.2m) / Total Assets 2.78b |
| B: -0.38 (Retained Earnings -1.06b / Total Assets 2.78b) |
| C: 0.11 (EBIT TTM 310.0m / Avg Total Assets 2.72b) |
| D: 1.48 (Book Value of Equity 1.66b / Total Liabilities 1.12b) |
| Altman-Z'' = 2.59 = A |
| DSRI: 1.04 (Receivables 270.9m/242.6m, Revenue 1.74b/1.61b) |
| GMI: 1.00 (GM 44.55% / 44.77%) |
| AQI: 0.92 (AQ_t 0.60 / AQ_t-1 0.65) |
| SGI: 1.08 (Revenue 1.74b / 1.61b) |
| TATA: -0.05 (NI 276.1m - CFO 401.4m) / TA 2.78b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of October 19, 2026, the stock is trading at USD 47.06 with a total of 884,708 shares traded. Over the past week, the price has changed by +1.05%, over one month by +2.91%, over three months by -1.18% and over the past year by +3.84%.
Current recommended Stop Loss: 45.30 (which is 3.7% or 1.7 ATR below the current price).
Zurn Elkay Water Solutions has received a consensus analysts rating of 3.70. Therefore, it is recommended to hold ZWS.
- StrongBuy: 3
- Buy: 1
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 58 | 23.2% |
P/E Trailing = 29.3106
P/E Forward = 22.8833
P/S = 4.381
P/B = 4.6767
P/EG = 1.525
Revenue TTM = 1.74b USD
EBIT TTM = 310.0m USD
EBITDA TTM = 396.2m USD
Long Term Debt = 497.7m USD (from longTermDebt, last quarter)
Short Term Debt = 16.8m USD (from shortTermDebt, last quarter)
Debt = 601.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 51.4m
Net Debt = 236.9m USD (calculated: Debt 601.9m - CCE 365.0m)
Enterprise Value = 8.06b USD (7.83b + Debt 601.9m - CCE 365.0m)
Interest Coverage Ratio = 11.97 (Ebit TTM 310.0m / Interest Expense TTM 25.9m)
EV/FCF = 21.50x (Enterprise Value 8.06b / FCF TTM 375.1m)
FCF Yield = 4.65% (FCF TTM 375.1m / Enterprise Value 8.06b)
FCF Margin = 21.58% (FCF TTM 375.1m / Revenue TTM 1.74b)
Net Margin = 15.89% (Net Income TTM 276.1m / Revenue TTM 1.74b)
Gross Margin = 44.77% ((Revenue TTM 1.74b - Cost of Revenue TTM 959.8m) / Revenue TTM)
Gross Margin QoQ = 49.77% (prev 47.53%)
Tobins Q-Ratio = 2.90 (Enterprise Value 8.06b / Total Assets 2.78b)
Interest Expense / Debt = 4.30% (Interest Expense 25.9m / Debt 601.9m)
Taxrate = 24.10% (86.6m / 359.3m)
NOPAT = 235.3m (EBIT 310.0m * (1 - 24.10%))
Current Ratio = 3.05 (Total Current Assets 953.1m / Total Current Liabilities 312.2m)
Debt / Equity = 0.36 (Debt 601.9m / totalStockholderEquity, last quarter 1.66b)
Debt / EBITDA = 0.60 (Net Debt 236.9m / EBITDA 396.2m)
Debt / FCF = 0.63 (Net Debt 236.9m / FCF TTM 375.1m)
Total Stockholder Equity = 1.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.16% (Net Income 276.1m / Total Assets 2.78b)
RoE = 17.09% (Net Income TTM 276.1m / Total Stockholder Equity 1.62b)
RoCE = 14.67% (EBIT 310.0m / Capital Employed (Equity 1.62b + L.T.Debt 497.7m))
RoIC = 9.81% (NOPAT 235.3m / Invested Capital 2.40b)
WACC = 8.46% (E(7.83b)/V(8.43b) * Re(8.86%) + D(601.9m)/V(8.43b) * Rd(4.30%) * (1-Tc(0.24)))
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.69 | Cagr: -1.65%
[DCF] Terminal Value 77.61% ; FCFF base≈337.7m ; Y1≈387.1m ; Y5≈569.7m
[DCF] Fair Price = 49.27 (EV 8.41b - Net Debt 236.9m = Equity 8.17b / Shares 165.9m; r=8.46% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.51 | EPS CAGR: 25.01% | SUE: 1.90 | # QB: 11
Revenue Correlation: 96.22 | Revenue CAGR: 5.57% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.50 | Chg30d=+0.00% | Revisions=+62% | Analysts=10
EPS current Year (2026-12-31): EPS=1.83 | Chg30d=+0.00% | Revisions=+79% | GrowthEPS=+20.5% | GrowthRev=+9.3%
EPS next Year (2027-12-31): EPS=2.04 | Chg30d=+0.11% | Revisions=+25% | GrowthEPS=+11.2% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: +80% (up=21, down=1)